Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia

Experimental Hematology

Volumn 30, Issue 9, 2002, Pages 1029-1035

  Greiner, Jochen ^a   Ringhoffer, Mark ^a   Taniguchi, Masanori ^a   Schmitt, Anita ^a   Kirchner, Dieter ^a   Krähn, Gertraud ^a   Heilmann, Volker ^a   Gschwend, J ^a   Bergmann, Lothar ^a   Döhner, Hartmut ^a   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIA ANTIGEN; MESSENGER RNA; RECEPTOR FOR HYALURONAN ACID MEDIATED MOTILITY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOIMMUNE DISEASE; BREAST CARCINOMA; CELL GROWTH; CELL MOTILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; HEALTH STATUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MONONUCLEAR CELL; NORMAL HUMAN; OVARY CARCINOMA; PLACENTA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; SAMPLING; SEROLOGY; SOLID TUMOR; TESTIS; THYMUS; VOLUNTEER; WESTERN BLOTTING;

ACUTE DISEASE; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, CD44; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA; COMPUTER SYSTEMS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; KIDNEY NEOPLASMS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MELANOMA; MONOCYTES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR STEM CELLS;

EID: 18644385334     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00874-3     Document Type: Article

References (49)

1. Phillips G.L., Reece D.E., Shepherd J.D.et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood. 77:1991;1429.
2. Cassileth P.A., Lynch E., Hines J.D.et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 79:1992;1924.
3. Zittoun R.A., Mandelli F., Willemze R.et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 332:1995;217.
4. Kolb H.J., Mittermüller J., Clemm C.et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462.
5. Kolb K.J., Schattenberg A., Goldman J.M.et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 86:1995;2041.
6. Porter D.L., Roth M.S., McGarigle C., Ferrara J.L., Antin J.H. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 330:1994;100.
7. Foa R., Fierro M.T., Tosti S., Meloni G., Gavosto F., Mandelli F. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leuk Lymphoma. 1:1990;113.
8. Jahn B., Bergmann L., Weidmann E.et al. Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. Leuk Res. 19:1995;73.
9. Choudhury A., Liang J.C., Thomas E.K.et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 93:1999;780.
10. Chen Y.-T., Scanlan M.J., Obata Y., Old L.J. Cancer vaccines. Rosenberg S.A. Principles and Practice of the Biologic Therapy of Cancer. 3rd Ed:2000;Lippincott Williams & Wilkins, Philadelphia. 557p.
11. Sahin U., Türeci Ö, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol. 9:1997;709.
12. Scanlan M.J., Chen Y.T., Williamson B.et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 76:1998;652.
13. Scanlan M.J., Gordan J.D., Williamson B.et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 83:1999;456.
14. SEREX Database: http://www.licr.org/SEREX.htm
15. Jäger E., Chen Y.T., Drijfhout J.W.et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1. definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes J Exp Med. 187:1998;265.
16. Sahin U., Türeci Ö, Schmitt H.et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 92:1995;11810.
17. Greiner J., Ringhoffer M., Simikopinko O.et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia (AML). Exp J Hematol. 28:2000;1413.
18. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156.
19. Crainie M., Belch A.R., Mant M.J., Pilarski L.M. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma. identification of three distinct RHAMM variants Blood. 93:1999;1684.
20. Biéche I., Laurendeau I., Tozlu S.et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 59:1999;2759.
21. Wang C., Entwistle J., Hou G., Li Q., Turley E.A. The characterization of a human RHAMM cDNA. conservation of the hyaluronan-binding domains Gene. 174:1996;299.
22. Sherman L., Sleeman J., Herrlich P., Ponta H. Hyaluronate receptors. key players in growth, differentiation, migration and tumor progression Curr Opin Cell Biol. 6:1994;726.
23. Yang B., Zhang L., Turley E.A. Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. J Biol Chem. 268:1993;8617.
24. Hamann K.J., Dowling T.L., Neeley S.P., Grant J.A., Leff A.R. Hyaluronic acid enhances cell proliferation during eosinopoiesis through the CD44 surface antigen. J Immunol. 154:1995;4073.
25. Assmann V., Kern H.F., Elsässer H.P. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res. 2:1996;1607.
26. Teder P., Bergh J., Heldin P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. Cancer Res. 55:1995;3908.
27. Pilarski L.M., Masellis-Smith A., Belch A., Yang B., Savani R.C., Turley E.A. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells. a mediator in B cell malignancy? Leuk Lymphoma. 14:1994;363.
28. Turley E.A., Belch A.J., Poppema S., Pilarski L.M. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood. 81:1993;446.
29. Hall C.L., Yang B., Yang X.et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell. 82:1995;19.
30. Wang C., Thor A.D., Moore D.H. II et al. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res. 4:1998;567.
31. Spicer A.P., Roller M.L., Camper S.A.et al. The human and mouse receptors for hyaluronan-mediated motility, RHAMM, genes (HMMR) map to human chromosome 5q33.2-qter and mouse chromosome 11. Genomics. 30:1995;115.
32. Till K.J., Zuzel M., Cawley J.C. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res. 59:1999;4419.
33. Savani R.C., Cao G., Pööler P.M., Zaman A., Zhou Z., DeLisser H.M. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem. 276:2001;36770.
34. Scanlan M.J., Gout I., Gordon C.M.et al. Humoral immunity to human breast cancer. antigen definition and quantitative analysis of mRNA expression Cancer Immunity. 1:2000;4.
35. Bergmann L., Miething C., Maurer U.et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 90:1997;1217.
36. Maurer U., Weidmann E., Karakas T., Hölzer D., Bergmann L. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood. 90:1997;4230.
37. Oka Y., Udaka K., Tsuboi A.et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 164:2000;1873.
38. Wu C., Yang X.-F., McLaughlin S.et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 106:2000;705.
39. Yang X.-F., Wu C., McLaughlin S.et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 98:2001;7492.
40. Molldrem J., Dermime S., Parker K.et al. Targeted T-cell therapy for human leukemia. cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood. 88:1996;2450.
41. Molldrem J., Lee P.P., Wang C., Champlin R.E., Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myeloid leukaemia. Cancer Res. 59:1999;2675.
42. Dengler R., Münstermann U., Al-Batran S.et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukemic myeloid cells. Br J Haematol. 89:1995;250.
43. Itoh M., Watanabe M., Yamada Y.et al. HUB1 is an autoantigen frequently eliciting humoral immune response in patient with adult T cell leukemia. Int J Oncol. 14:1999;703.
44. Eichmüller S., Usener D., Dummer R., Stein A., Thiel D., Schadendorf D. Serological detection of cutaneous lymphoma-associated antigens. Proc Natl Acad Sci U S A. 98:2001;629.
45. Ikeda H., Lethe B., Lehmann F.et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6:1997;199.
46. Neumann E., Engelsberg A., Decker J.et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma. candidates for T-cell-based immunotherapies Cancer Res. 58:1998;4090.
47. Van Baren N., Chambost H., Ferrant A.et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukemia cells. Br J Haematol. 102:1998;1376.
48. Kessler J.H., Beekman N.J., Bres-Vloemans S.A.et al. Efficient identification of novel HLA-A 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 193:2001;73.
49. Ling M., Wen Y.J., Lim S.H. Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia. Blood. 92:1998;4764.